IL2 and hereditary clear cell renal cell carcinoma: Moreover, different phase I and II studies investigating the combination of IL-2 and RT in renal cell carcinoma, melanoma and non-small cell lung cancer are ongoing (NCT01884961, NCT02306954, NCT030226236, NCT03224871).